Table 2 The impact of adipocytes on breast cancer therapy
From: Cancer-associated adipocytes: emerging supporters in breast cancer
Therapeutic type | Therapeutic drug | Cancer cell type | Mechanism of therapeutic resistance | Ref. |
|---|---|---|---|---|
Chemotherapy | Doxorubicin | T47D, MDA-MB453, BT-474, MDA-MB436, MDA-MB231, M-Wnt and E0771 | Adipocytes induced an MVP-related DOX-resistant phenotype in BC cells | [104] |
Paclitaxel | MDA-MB-231 | Mammary-adipocyte-derived leptin upregulated CPT1B expression and FAO activity in BCSCs, thus promoting cancer cell stemness and chemoresistance | [25] | |
Hormonal therapy | Tamoxifen | MCF-7, MDA-MB-231, T47D and MDA-MB-435 | Mature adipocytes and their secretions were able to increase mammary cancer cell proliferation and to suppress the antiproliferative effect of tamoxifen | |
Radiotherapy | – | SUM159PT | Tumor-surrounding adipocytes fostered a radioresistant phenotype in breast tumors through the increasing expression of IL-6 in tumor cells | [109] |
– | Hs578T and 4T1 | Inflammatory cytokines produced by tumors increased ATX secretion of mammary adipocytes, and enhanced the ATX-LPA inflammatory cycle, thus resisting radiotherapy | ||
Immunotherapy | Trastuzumab | BT-474, SK-BR-3, MDA-MB-453, and MDA-MB-361 | Adipocytes inhibited trastuzumab-mediated ADCC in HER2-expressing BC cells via the secretion of soluble factors | [113] |
Anti-PD1/PD-L1 antibody | E0771 | Adipocyte PD-L1 prevented anti-PD-L1 antibody from activating important antitumor functions of CD8+ T cells | [114] |